Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is... see more

Recent & Breaking News (CSE:RVV)

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire December 29, 2021

UPDATE -- Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

GlobeNewswire December 3, 2021

Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

GlobeNewswire December 3, 2021

Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

GlobeNewswire November 23, 2021

Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant

GlobeNewswire November 16, 2021

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

GlobeNewswire November 11, 2021

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch

GlobeNewswire November 3, 2021

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin Microneedle Patch

GlobeNewswire November 3, 2021

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire October 26, 2021

Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF

GlobeNewswire September 21, 2021

Pharmather provides business highlights and releases annual financials for FY May 31, 2021

Stockhouse Editorial September 8, 2021

PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021

GlobeNewswire September 7, 2021

Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer

GlobeNewswire August 17, 2021

Revive Confirms No Material Undisclosed Information

GlobeNewswire August 12, 2021

Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline

GlobeNewswire August 10, 2021

IIROC Trade Resumption - RVV

PR Newswire July 15, 2021

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire July 15, 2021

IIROC Trading Halt - RVV

PR Newswire July 15, 2021

Revive Therapeutics Approved to Trade on the OTCQB Market

GlobeNewswire June 25, 2021

Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics

GlobeNewswire June 17, 2021